All In Biotech

Free tool

FAERS Monitor: Copiktra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211155 or its brand name (Copiktra, Duvelisib). Reports on generic versions are filed under their own applications.

Reports

853

Serious

488

57% of reports

Hospitalization

268

Death reported

181

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication237
  • diarrhoea112
  • death111
  • off label use106
  • fatigue82
  • prescribed underdose65
  • product use issue58
  • nausea50
  • pneumonia42
  • pyrexia41
  • malignant neoplasm progression40
  • rash38
  • disease progression37
  • hospitalisation36
  • asthenia33

Reports by year received

View as table
YearReports
20152
201617
20177
201820
2019121
2020158
202198
202288
202368
202465
202596
2026113

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
prescribed underdoseSignal6580.663.85,019
product use in unapproved indicationSignal23723.621.25,163
malignant neoplasm progressionSignal409.67.1302
disease progressionSignal377.75.6211
product use issueSignal587.65.9329
hospitalisationSignal365.84.2138
diarrhoeaSignal1124.33.6287
pneumoniaSignal423.22.462
deathSignal1113.22.7170
off label useSignal1063.02.5144
pyrexiaSignal412.92.251
fatigueSignal822.62.182
astheniaSignal332.21.520
rashSignal382.11.623
nausea501.61.210

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.